Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France

2012 ◽  
Vol 167 (3) ◽  
pp. 643-648 ◽  
Author(s):  
A. Maza ◽  
M.A. Richard ◽  
F. Aubin ◽  
J.P. Ortonne ◽  
S. Prey ◽  
...  
Keyword(s):  
Observational Study ◽  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Significant Delay

scholarly journals IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis

2022 ◽  
Vol 23 (1) ◽  
pp. 555
Author(s):  
Xing Wang ◽  
Hannah Kaiser ◽  
Amanda Kvist-Hansen ◽  
Benjamin D. McCauley ◽  
Lone Skov ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Plasma Proteins ◽  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Atherosclerotic Cardiovascular Disease ◽  
Strong Correlations ◽  
Potential Marker ◽  
Chronic Inflammatory Condition ◽  
Circulating Levels ◽  
Potential Biomarkers

Psoriasis is a chronic inflammatory condition associated with atherosclerotic cardiovascular disease (CVD). Systemic anti-psoriatic treatments mainly include methotrexate and biological therapies targeting TNF, IL-12/23 and IL-17A. We profiled plasma proteins from patients with moderate-to-severe psoriasis to explore potential biomarkers of effective systemic treatment and their relationship to CVD. We found that systemically well-treated patients (PASI < 3.0, n = 36) had lower circulating levels of IL-17 pathway proteins compared to untreated patients (PASI > 10, n = 23). Notably, IL-17C and PI3 were decreased with all four examined systemic treatment types. Furthermore, in patients without CVD, we observed strong correlations among IL-17C/PI3/PASI (r ≥ 0.82, p ≤ 1.5 × 10−12) pairs or between IL-17A/PASI (r = 0.72, p = 9.3 × 10−8). In patients with CVD, the IL-17A/PASI correlation was abolished (r = 0.2, p = 0.24) and the other correlations were decreased, e.g., IL-17C/PI3 (r = 0.61, p = 4.5 × 10−5). Patients with moderate-to-severe psoriasis and CVD had lower levels of IL-17A compared to those without CVD (normalized protein expression [NPX] 2.02 vs. 2.55, p = 0.013), and lower IL-17A levels (NPX < 2.3) were associated with higher incidence of CVD (OR = 24.5, p = 0.0028, 95% CI 2.1–1425.1). As a result, in patients with moderate-to-severe psoriasis, we propose circulating IL-17C and PI3 as potential biomarkers of effective systemic anti-psoriatic treatment, and IL-17A as potential marker of CVD.

Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study

2014 ◽  
Vol 24 (6) ◽  
pp. 662-669 ◽  
Author(s):  
Francisco Vanaclocha ◽  
Isabel Belinchón ◽  
José L. Sánchez-Carazo ◽  
Raquel Rivera ◽  
José M. Carrascosa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Cardiovascular Risk Factors ◽  
Systemic Treatment ◽  
Descriptive Study ◽  
Severe Psoriasis

scholarly journals Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study

2019 ◽  
Vol 115 (4) ◽  
pp. 721-728 ◽  
Author(s):  
Youssef A Elnabawi ◽  
Amit K Dey ◽  
Aditya Goyal ◽  
Jacob W Groenendyk ◽  
Jonathan H Chung ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Biologic Therapy ◽  
Severe Psoriasis ◽  
Coronary Artery Plaque

scholarly journals Systemic treatment for severe psoriasis in a patient with autoimmune cytopenia

2020 ◽  
Vol 6 (3) ◽  
pp. 224
Author(s):  
Mary Kathryn Abel ◽  
Raagini Suresh ◽  
Jodie Raffi ◽  
Kristin Razzeca ◽  
Jenny E. Murase
Keyword(s):  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Autoimmune Cytopenia

Systemic treatment of elderly patients with NSCLC: Results of a German prospective observational study.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e19052-e19052
Author(s):  
Karl Matthias Deppermann ◽  
Gert Hoeffken ◽  
Dieter Wuerflein ◽  
Matthias Feurer ◽  
Achim Rittmeyer ◽  
...  
Keyword(s):  
Observational Study ◽  
Elderly Patients ◽  
Prospective Observational Study ◽  
Systemic Treatment

Systemic Treatment of Severe Psoriasis

1991 ◽  
Vol 324 (5) ◽  
pp. 333-334 ◽  
Author(s):  
Nicholas J. Lowe
Keyword(s):  
Systemic Treatment ◽  
Severe Psoriasis

scholarly journals Recommendations Russian Society of Dermatovenerologists and Cosmetologists for systemic treatment of psoriasis during the pandemic COVID-19

2020 ◽  
Vol 96 (2) ◽  
pp. 9-13
Author(s):  
Alexey A. Kubanov ◽  
Andrey L. Bakulev ◽  
Muza M. Kokhan ◽  
Olga Yu. Olisova ◽  
ALexey V. Samtsov ◽  
...  
Keyword(s):  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Published Data ◽  
Russian Society ◽  
Clinical Recommendations

Below you will find the analysis of the first published data and international clinical recommendations for the systemic treatment of patients with moderate and severe psoriasis in the context of the COVID-19 pandemic in different countries (France, Italy, USA, Spain, and Germany).

Sign in / Sign up

Export Citation Format

Share Document